Locations
Conditions
Treatments
Institutions
Resources
For researchers
About us
Clinical trials
Phase 1/2, Open-label Study of ETX-929, a KRAS Inhibitor in Participants With Advanced Solid Tumors
Apply
ETX-929
Phase 1/2, Open-label Study of ETX-929, a KRAS Inhibitor in Participants With Advanced Solid Tumors
Basic information
Step 1/5
Provide your basic information
Age
ZIP code
Back
Next step